IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-337)

Pilauri, et al.

Serial No.: 10/600,389

For: Methods for Protein Analyses and Protein
Expression in Multicellular Organisms
and Cells Therefrom

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-337)

Examiner: 1632

Examiner: TBD

## TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
  - a. Supplemental Information Disclosure Statement (IDS)
  - b. Form PTO-1449 (4 sheets)
  - c. Return Receipt Postcard
- 2. With respect to fees:
  - a. X No fee is required
- 3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 13, 2004.

Date: August 13, 2004

Kevin E. Noonan Reg. No. 35,303

McDonnell, Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive

espectfully submitted,

Chicago, IL 60606

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 03-337)

In the	Applica	ation of:	)		
	Pilaur	i, et al.	)	Art Unit:	1632
Serial	No.:	10/600,389	)		
Filed:		June 20, 2003	)	Examiner: T	TBD
For:	Expres	ods for Protein Analyses and Protein ssion in Multicellular Organisms ells Therefrom	) ) )		

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Kevin E. Noonan Reg. No. 35,303

Date: August 13, 2004

Substitute for form	1449A/PTO		Complete if Known		
21.6 y			Application No.	10/600,389	
1 6 2004 PM	FORMATION	DISCLOSU	Filing Date:	May 25, 2000	
الم				First Named Inventor	Pilauri et al.,
(use as many sheets as necessary)				Group Art Unit	1632
TRADENA.	(use as many shee	ets as necessary)		Examiner Name	
Sheet	1	of	1	Attorney Docket No.	00-337

_				U.S. PATENT DOCUMENT	<u>S</u>	247211
Examiner Initials*	Cite No.	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Figures Appear
		5,283,173		The Research Foundation of State University of New York	02-01-1994	

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines	T	
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Figures Appear	T <sup>6</sup>	
				<u> </u>					

OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>				
		PENG et al., "Gene activation by interaction of an inhibitor with a cytoplasmic signaling protein" PNAS 99(13)8548-8553 (June 25, 2002).					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.